305
Views
14
CrossRef citations to date
0
Altmetric
Original Research

Facial skin revitalization with CPM®-HA20G: an effective and safe early intervention treatment

, , , &
Pages 563-572 | Published online: 13 Aug 2019
 

Abstract

Background

Hyaluronic acid (HA) fillers are popular for the treatment of signs of facial skin aging.

Objective

The objective of this study was to confirm the performance and safety of a new cohesive polydensified matrix HA filler ([CPM®-HA20G, Belotero Revive®, lidocaine-free], Merz Pharmaceuticals GmbH, Frankfurt, Germany) for the treatment of early signs of facial skin aging by use of biophysical measurements as well as subject and investigator satisfaction.

Methods

Twenty-five healthy female subjects with signs of facial skin aging were enrolled in this open-label, rater-blinded, observational post-market clinical follow-up study, and received 20 micropuncture treatments of 50 µL CPM®-HA20G each into the lower cheek area at three injection visits 4 weeks apart. Objective biophysical assessments were conducted to demonstrate effects on viscoelastic properties of the skin, surface roughness, tone and radiance, and hydration, at baseline and at all follow-up visits up to 36 weeks.

Results

CPM®-HA20G significantly increased gross elasticity of the skin (at weeks 9 and 12), skin firmness (up to week 24), skin tone and radiance and skin hydration (all up to 36 weeks). Significant reduction of skin fatigue (up to 9 weeks), skin roughness (up to 28 weeks), and redness (up to 36 weeks) was also observed. Subjects and blinded investigator were highly satisfied with the treatment outcomes. The treating investigator reported a high level of satisfaction with the ease of injection and the clinical performance of the device. Moreover, data demonstrated a good safety profile of the device.

Conclusion

CPM®-HA20G is considered to be an effective and safe HA injectable for skin revitalization in patients suffering from signs of skin aging and loss of skin elasticity. It seems to be a perfect early intervention approach in patients that do not need volumizing treatment and a combination approach in older patients with more pronounced aging.

Acknowledgments

The authors would like to thank all members of the BELOVE Study Group. This study was sponsored by Merz Pharmaceuticals GmbH.

Disclosure

Angelika Hanschmann and Matthias Hofmann are employees of Merz Pharmaceuticals GmbH. Martina Kerscher has conducted clinical trials and acted as a speaker for Merz Pharmaceuticals GmbH. Martina Kerscher also reports educational grants and products from Merz Pharmaceuticals, during the conduct of the study and received educational grants from Galderma/ Q Med as the Advisory Board Member. Dominique Hertz-Kleptow reports grants from Merz Pharmaceuticals, during the conduct of the study. The authors report no other conflicts of interest in this work.